Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy
Patients with malignant tumors frequently suffer during disease progression from a syndrome referred to as cancer cachexia (CaCax): CaCax includes skeletal muscle atrophy and weakness, loss of bodyweight, and fat tissues. Currently, there are no FDA (Food and Drug Administration) approved treatments...
Main Authors: | Volker Adams, Victoria Gußen, Sergey Zozulya, André Cruz, Anselmo Moriscot, Axel Linke, Siegfried Labeit |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/10/2272 |
Similar Items
-
Regulation of Glucose Metabolism by MuRF1 and Treatment of Myopathy in Diabetic Mice with Small Molecules Targeting MuRF1
by: Siegfried Labeit, et al.
Published: (2021-02-01) -
Expression of MuRF1 or MuRF2 is essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model
by: Thanh Nguyen, et al.
Published: (2020-04-01) -
Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy
by: Fernando Ribeiro, et al.
Published: (2023-02-01) -
Removal of MuRF1 Increases Muscle Mass in Nemaline Myopathy Models, but Does Not Provide Functional Benefits
by: Johan Lindqvist, et al.
Published: (2022-07-01) -
Emerging Strategies Targeting Catabolic Muscle Stress Relief
by: Mattia Scalabrin, et al.
Published: (2020-06-01)